MedPath

Biodiversity Interventions for Well-Being

Not Applicable
Active, not recruiting
Conditions
Immune System Diseases
Nature, Human
Well-Being, Psychological
Microbial Colonization
Interventions
Other: Rewilding
Registration Number
NCT06353035
Lead Sponsor
Natural Resources Institute Finland
Brief Summary

Biodiversity is essential for nature and human well-being. Land use has reduced biodiversity in cities, which weakens the functionality of the urban ecosystems and the well-being of citizens. This may also increase the risk of immune-mediated disorders among urban dwellers.

In Biodiversity interventions for well-being (BIWE), microbial biodiversity interventions are performed to increase biodiversity in urban built areas. Results from the intervention trials are combined with publicly available land cover and ecological data. These are analyzed from the viewpoint of shifts in ecosystems and human well-being and immune regulation, ecological quality, and urban planning.

The investigators set up an intervention study in which urban private yards are rewilded with diverse vegetation and decaying deadwood and plant residuals. The investigators aim to evaluate the effect of rewilding, and yard management practices on commensal microbiome, cortisol levels and well-being and salivary cytokine levels, and gene pathways.

Detailed Description

Our specific aims are:

To assess if rewilding diversifies health-associated skin microbiota and is associated with salivary cytokine levels, gene pathways, cortisol levels and commensal microbiota.

Assess whether there are patterns in the microbiome associated with the salivary cytokine levels and hair cortisol levels.

Assess whether rewilding affects health and psychological measures, such as Perceived Stress Scale (PSS), Warwick-Edinburgh Mental Wellbeing Scale (SWEMWS), Depression Scale (DEPS) and Nature Relatedness Scale (NR6).

The investigators will recruit approximately 42 (21 study subjects per treatment) subjects living in a detached house or terraced house in urban areas and aged between 18-72.

The medical exclusion criteria include immunosuppressive medications, immune deficiencies, a disease affecting immune response (e.g., colitis ulcerosa, rheumatoid arthritis, Crohn's disease, diabetes), cancer diagnosis within the last year or on-going cancer treatment. Other exclusion criteria include incompetency and living outside city area.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
30
Inclusion Criteria
  • Living in a detached or terraced house in urban area
Exclusion Criteria
  • Immunosuppressive medications
  • Immune deficiencies
  • a disease affecting immune response (e.g., colitis ulcerosa, rheumatoid arthritis, Crohn's disease, diabetes)
  • cancer diagnosis within the last year or on-going cancer treatment
  • Incompetency
  • Living outside city area.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
RewildingRewildingPrivate yards of the intervention study subjects will be modified with berry bushes, fruit trees, perennial yard plants, meadow flowers, cultivation boxes, organic mulch materials, decaying deadwood, leaf compost and organic plant growing media with high microbial diversity.
Primary Outcome Measures
NameTimeMethod
Skin GammaproteobacteriaBaseline, 3 month, 1 year, 2 year, 3 year, 4 year, 5 year

Difference on skin gammaproteobacterial diversity between rewilding and control group

Secondary Outcome Measures
NameTimeMethod
Cortisol levelsBaseline, 3 month, 1 year, 2 year, 3 year, 4 year, 5 year

Cortisol levels measured from hair samples

Salivary cytokinesBaseline, 3 month, 1 year, 2 year, 3 year, 4 year, 5 year

Interleukin-6 and -10 measured from saliva

Difference in taxonomies of skin, saliva and stool microbiotaBaseline, 3 month, 1 year, 2 year, 3 year, 4 year, 5 year

It will be analyzed if microbial communities are different between treatments

Difference in microbial gene pathways of saliva and stool microbiotaBaseline, 3 month, 1 year, 2 year, 3 year, 4 year, 5 year

Will be analyzed with shotgun sequencing if gene pathways are different between treatments

Perceived Stress ScaleBaseline, 3 month, 1 year, 2 year, 3 year, 4 year, 5 year

Lower score on a perceived stress scale among intervention treatment compared to control that indicates lower perceived stress levels among intervention treatment. Minimum 0, maximum 40.

Nature Relatedness ScaleBaseline, 3 month, 1 year, 2 year, 3 year, 4 year, 5 year

Higher score on a Nature Relatedness scale among intervention treatment compared to control that indicates stronger sense of connectedness to nature among intervention treatment. Minimum 6, maximum 30.

Difference in diversity (Alpha and beta diversity) of skin, saliva and stool microbiotaBaseline, 3 month, 1 year, 2 year, 3 year, 4 year, 5 year

It will be analyzed if microbial communities are different between treatments

Difference in observed species richness of skin, saliva and stool microbiotaBaseline, 3 month, 1 year, 2 year, 3 year, 4 year, 5 year

It will be analyzed if microbial communities are different between treatments

Metabolites in urineBaseline, 3 month, 1 year, 2 year, 3 year, 4 year, 5 year

Metabolites of harmful substances are measured from the urine sample.

Warwick-Edinburgh Mental Wellbeing ScaleBaseline, 3 month, 1 year, 2 year, 3 year, 4 year, 5 year

Higher score on a Warwick-Edinburhg Mental Wellbeing scale among intervention treatment compared to control that indicates better mental well-being among intervention treatment. Minimum 14, maximum 70.

Depression ScaleBaseline, 3 month, 1 year, 2 year, 3 year, 4 year, 5 year

Lower score on a Depression scale among intervention treatment compared to control that indicates lower levels of depression symptoms among intervention treatment. Minimum 0, maximum 60.

Trial Locations

Locations (1)

Natural Resources Institute Finland

🇫🇮

Helsinki, Uusimaa, Finland

© Copyright 2025. All Rights Reserved by MedPath